Clinical trial
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
NCT04593758 is registered in ClinicalTrials.gov with Cornerstone Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
- Lead sponsor
- Cornerstone Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 1, 2021
- Completion date
- March 9, 2023
- Enrollment
- 16 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.